
|Videos|December 4, 2021
Lutetium 177 PSMA enhances QOL in patients with mCRPC
Author(s)Urology Times staff
"The results of this trial impacted practice globally,” says Michael J. Morris, MD.
Advertisement
In this video, Michael J. Morris, MD, discusses the background, findings, and takeaways of the VISION trial, which was presented recently at the 2021 Society of Urologic Oncology Annual Meeting. Morris is the section head of prostate cancer in the GU oncology service at the Memorial Sloan Kettering Cancer Center in New York, New York.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
HHS requests testosterone therapy label updates, citing new safety data
2
Unmet needs and emerging solutions in MRI-guided prostate cancer care
3
Microbial dysbiosis may predict response to CBM588 in mRCC
4
Eugene Pietzak, MD, on pembrolizumab plus BCG for BCG-naïve “very high risk” T1 NMIBC
5











